HALO Macrodissection Solutions

HALO Macrodissection Solutions is a suite of AI-powered tools from Indica Labs designed to standardize tumor content quantification, eliminate manual estimation, and streamline region of interest (ROI) selection for downstream molecular analysis. By rapidly identifying samples that fall below molecular testing thresholds, the platform ensures optimal tumor concentration, reducing time and cost while improving precision, consistency, and confidence in results. HALO Macrodissection Solutions are intended for Research Use Only and are not intended for clinical diagnostic use.

The suite currently includes four tissue-specific algorithms — Lung Macrodissect AI, CRC Macrodissect AI, Breast Macrodissect AI, and Prostate Macrodissect AI (coming soon) — each tailored to the unique histological characteristics of their respective cancer types. All algorithms operate on H&E whole slide images and are fully deployed within HALO AP®, Indica Labs' AI-powered anatomic pathology platform.

Lung Macrodissect AI

• Inputs: H&E whole slide images from primary and metastatic NSCLC resections, excisions, and/or core needle biopsies
• Tissue detection and artifact exclusion
• Benign epithelial identification
• Cell phenotyping
• Density heatmap generation
• Percent tumor content for whole slide image and dissection ROIs
• Analytical validation demonstrated tumor cell precision of 0.94 and an F1 score of 0.94
• Inter-pathologist agreement on lung tumor content improved significantly when using Lung Macrodissect AI compared with manual assessment alone

CRC Macrodissect AI

• Inputs: H&E whole slide images from primary and metastatic colorectal cancer resections, excisions, and/or core needle biopsies
• Tissue detection and artifact exclusion
• Benign epithelial identification
• Necrotic cell identification
• Cell phenotyping
• Density heatmap generation
• Percent tumor content and percent necrotic cells for whole slide image and dissection ROIs
• Analytical validation demonstrated tumor cell precision of 0.96 and an F1 score of 0.97
• Inter-pathologist agreement on CRC tumor content improved significantly when using CRC Macrodissect AI compared with manual assessment alone

Breast Macrodissect AI

• Inputs: H&E whole slide images from primary invasive breast carcinoma resections, excisions, and/or core needle biopsies
• Tissue detection and artifact exclusion
• Non-invasive epithelia detection
• Identification of regions of necrosis, RBCs, and necrotic nuclei
• Cell phenotyping
• Density heatmap generation
• Percent tumor content and percent necrotic cells for whole slide image and dissection ROIs
• Analytical validation demonstrated tumor cell precision of 0.93 and an F1 score of 0.92

Automated Workflow

• H&E slides prepared from tissue specimens are scanned into HALO AP®
• Advanced algorithms automatically detect tissue and eliminate background and artifacts
• Algorithms distinguish benign epithelium from tumor regions
• Integrated cell counts and tumor density heatmaps provide pathologists with clear, data-driven insights
• Precise ROIs are defined for downstream macrodissection based on quantitative outputs

Key Benefits

• Confidence in results: Accurate tumor content quantification standardizes downstream molecular analysis and ensures reproducibility
• Streamlined workflows: Automated tumor content analysis accelerates ROI selection and saves staff time and resources
• Auditable process: A transparent, auditable macrodissection workflow ensures consistency and confidence across cases

Integration with Xyall Tissector

• HALO Macrodissection Solutions can integrate with Xyall's Tissector automated macrodissection platform
• Creates a comprehensive, auditable end-to-end solution that is more precise and efficient than conventional methods
• A detailed audit trail is generated for each case, including pre- and post-dissection images
• Ensures greater accuracy, consistency, and transparency throughout the macrodissection process

HALO Macrodissection Solutions are deployed and fully integrated within HALO AP®, Indica Labs' AI-powered, pathologist-driven enterprise digital pathology platform. HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland, and provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR. In the USA, HALO AP® is For Research Use Only and is not FDA cleared for clinical diagnostic use.